Supernus Pharmaceuticals Inc/ US8684591089 /
9/3/2024 10:00:00 PM | Chg. -0.4500 | Volume | Bid12:36:25 AM | Ask12:36:25 AM | High | Low |
---|---|---|---|---|---|---|
34.7100USD | -1.28% | 380,700 Turnover: 8.46 mill. |
33.2300Bid Size: 100 | 35.7400Ask Size: 100 | 34.9300 | 34.3900 |
GlobeNewswire
8/28
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
GlobeNewswire
8/19
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
GlobeNewswire
7/23
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call ...
GlobeNewswire
5/30
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
5/23
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epile...
GlobeNewswire
5/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
5/12
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
5/9
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa St...
GlobeNewswire
5/2
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
4/24
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call o...
GlobeNewswire
4/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...